CASP8 and cancer: Consistently, the levels of FLIP proteins, the main modulators of Caspase-8 enzymatic activation, are dramatically upregulated in several cancers and correlate with a poorer clinical outcome, likely related to FLIP’s cell death inhibitory function on Caspase-8 [9].